Innovative Therapies for the Treatment of Acute Pain

Read More

About AcelRx

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative sublingual therapies for the treatment of moderate-to-severe acute pain in medically supervised settings.

Sublingual Sufentanil

Sufentanil has demonstrated rapid uptake through mucosal tissues, and has a high therapeutic index in animal models.1 These characteristics make sufentanil a promising candidate for non-invasive treatment of moderate-to-severe acute pain.

proprietary sublingual technology for acute pain relief

AcelRx's non-invasive, sublingual formulation technology efficiently delivers highly lipophilic drugs with consistent pharmacokinetic profiles. The Company's two late-stage product candidates, ARX-04 and Zalviso™, were developed using this proprietary technology.

Learn More

  1. Mather LE. Opioids: a pharmacologist's delight! Clin Exp Pharmacol Physiol 1995; 22:833-6.